Schultz, E.S., Schuler-Thurner, B., Stroobant, V., Jenne, L., Berger, T.G., Thielemanns, K., van der Bruggen, P., and Schuler, G.: Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 2004, 172:1304–1310.
16-16 T cells expressing chimeric antigen receptors are an effective treatment in some leukemias.
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509–1518.
Stromnes, I.M., Schmitt, T.M., Chapuis, A.G., Hingorani, S.R., and Greenberg, P.D.: Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol. Rev. 2014, 257:145–164.
16-17 Monoclonal antibodies against tumor antigens, alone or linked to toxins, can control tumor growth.
Bradley,A.M., Devine, M., and DeRemer, D.: Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am. J. Health Syst. Pharm. 2013, 70:589–597.
Hortobagyi, G.N.: Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 2005, 353:1734–1736.
Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J., and Pastan, I.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001, 345:241–247.
Park, S., Jiang, Z., Mortenson, E.D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N.K., Greene, M., et al.: The therapeutic effect of antiHER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160–170.
Tol, J., and Punt, C.J.: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther. 2010, 32:437–453.
Veeramani, S., Wang, S.Y., Dahle, C., Blackwell, S., Jacobus, L., Knutson, T., Button, A., Link, B.K., and Weiner, G.J.: Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011, 118:3347–3349.
Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D.Y., Diéras, V., Guardino, E., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367:1783–1791.